Qualcomm Life, the San Diego healthtech subsidiary of Qualcomm Inc., is teaming up with Medtronic Plc to develop disposable glucose monitoring systems for type 2 diabetes patients.
The companies plan to develop small and affordable wireless products that monitor glucose levels in real time and generate data that can be analyzed later, according to a joint news release. The partnership will focus first on developing a disposable product for physicians monitoring type 2 diabetes patients.
The duo will use Qualcomm Life’s expertise in wireless systems to create cheaper and easier-to-use continuous glucose monitoring (CGM) systems, which will include a new sensor and a smaller design, according to the release.
There may be new hope for diabetics who have lost the use of a limb due to vascular disease.
An experimental therapy causes new vessels to grow and restore blood flow in the limbs of diabetic mice with severe vascular disease, and the inventors of the injectable regenerative gel say it could be ready for clinical testing in just a few years.
Salk Institute scientists say they've discovered a key ingredient needed to make functional insulin-producing beta cells. With that knowledge, the scientists say they can realize a dream in treating Type 1 diabetes: growing replacement beta cells from the patients themselves.
If these replacement cells can be implanted and protected, they will make insulin as the body needs, just as the original cells do. That means type 1 diabetes would, for the first time ever, be curable.
Insurance provider Blue Cross Blue Shield of Michigan, in its quest for better and cheaper patient care, has formed a new partnership with Ann Arbor, MI-based startup Hygieia.
As part of the arrangement, Blue Cross will invest an undisclosed amount in the company, which has developed a digital insulin guidance system called d-Nav, and launch a one-year, 1,000-patient demonstration project with diabetic patients at Oakland Southfield Physicians, a healthcare provider network in Southeast Michigan.
Attempting to free people with diabetes from frequent finger-pricks and drug injections, researchers have created an electronic skin patch that senses excess glucose in sweat and automatically administers drugs by heating up microneedles that penetrate the skin.
El grupo anglo-suizo Glencore registró pérdidas netas anuales de 4.562,76 millones de euros en 2015.
Ese dato revelado por la multinacional dedicada a la compraventa y producción de materias primas, en un comunicado divulgado en la Bolsa de Londres, contrasta con el obtenido en 2014, cuando obtuvo beneficios después de impuestos de 2.308 millones de dólares (2.121 millones de euros).
En la citada nota, Glencore informó también de que su resultado bruto de explotación (ebitda) fue el pasado año de 8.694 millones de dólares (7.992,28 millones de euros), lo que supuso un incremento del 32% frente a 2014, cuando fue de 12.764 millones de dólares (11.733 millones de euros).
iabetic neuropathy is the number one cause of amputation in the world – and it affects as many as 70% of the 30 million-plus people in the US who suffer from diabetes, costing the economy as much as $10 billion annually. Diabetics with the condition suffer a loss of sensitivity in nerve endings in their legs and feet – meaning that, since they have less feeling in their feet they may end up damaging them extensively before they realized that they have a problem.
But a new invention developed jointly at Hebrew University and Hadassah Hospital – the SenseGo “smart sock” – could help temper the effects of diabetic neuropathy by offering a “sensor assist” to the feet.
Fully functional pancreatic cells have been cultured by scientists, potentially meaning the end of daily insulin injections for sufferers of the disease. The lab-made cells were tested in mice, and they successfully prevented the mice from developing diabetes.
The new research will mean that pancreatic cells can be developed to match each individual diabetes patient's DNA. This is the first time fully working pancreatic cells have been developed successfully in a lab, a breakthrough for diabetes research.
Un nuevo sistema que integra modelos matemáticos y estadísticos permite la predicción precoz y personalizada de la diabetes tipo 2 (DT2) a partir de la historia clínica electrónica de cada paciente.
We’ve been covering news of the GlucoTrack non-invasive glucometer for almost a decade now, and finally Integrity Applications, the company behind the device, is moving toward clinical trials potential regulatory approval in the U.S. The Israeli firm already received the CE mark in Europe for the GlucoTrack model DF-F two years ago, and the same device is in the pre-submission documents filed with the FDA.
